Copyright Reports & Markets. All rights reserved.

Global Equine Immunoglobulin and F(ab')2 Products Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Equine Immunoglobulin and F(ab')2 Products Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Tetanus Antitoxins
    • 1.3.3 Snake Antivenoms
    • 1.3.4 Anti-rabies Sera
    • 1.3.5 Other
  • 1.4 Market Analysis by Sales Channels
    • 1.4.1 Overview: Global Equine Immunoglobulin and F(ab')2 Products Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
    • 1.4.2 Online Sales
    • 1.4.3 Offline Sales
  • 1.5 Market Analysis by Application
    • 1.5.1 Overview: Global Equine Immunoglobulin and F(ab')2 Products Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.5.2 Hospital
    • 1.5.3 Clinic
    • 1.5.4 Others
  • 1.6 Global Equine Immunoglobulin and F(ab')2 Products Market Size & Forecast
    • 1.6.1 Global Equine Immunoglobulin and F(ab')2 Products Consumption Value (2021 & 2025 & 2032)
    • 1.6.2 Global Equine Immunoglobulin and F(ab')2 Products Sales Quantity (2021-2032)
    • 1.6.3 Global Equine Immunoglobulin and F(ab')2 Products Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Laboratorios Silanes
    • 2.1.1 Laboratorios Silanes Details
    • 2.1.2 Laboratorios Silanes Major Business
    • 2.1.3 Laboratorios Silanes Equine Immunoglobulin and F(ab')2 Products Product and Services
    • 2.1.4 Laboratorios Silanes Equine Immunoglobulin and F(ab')2 Products Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Laboratorios Silanes Recent Developments/Updates
  • 2.2 Emergent BioSolutions
    • 2.2.1 Emergent BioSolutions Details
    • 2.2.2 Emergent BioSolutions Major Business
    • 2.2.3 Emergent BioSolutions Equine Immunoglobulin and F(ab')2 Products Product and Services
    • 2.2.4 Emergent BioSolutions Equine Immunoglobulin and F(ab')2 Products Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Emergent BioSolutions Recent Developments/Updates
  • 2.3 Shanghai Serum Bio-Technology
    • 2.3.1 Shanghai Serum Bio-Technology Details
    • 2.3.2 Shanghai Serum Bio-Technology Major Business
    • 2.3.3 Shanghai Serum Bio-Technology Equine Immunoglobulin and F(ab')2 Products Product and Services
    • 2.3.4 Shanghai Serum Bio-Technology Equine Immunoglobulin and F(ab')2 Products Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Shanghai Serum Bio-Technology Recent Developments/Updates
  • 2.4 VINS Bioproducts
    • 2.4.1 VINS Bioproducts Details
    • 2.4.2 VINS Bioproducts Major Business
    • 2.4.3 VINS Bioproducts Equine Immunoglobulin and F(ab')2 Products Product and Services
    • 2.4.4 VINS Bioproducts Equine Immunoglobulin and F(ab')2 Products Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 VINS Bioproducts Recent Developments/Updates
  • 2.5 Bharat Serums and Vaccines
    • 2.5.1 Bharat Serums and Vaccines Details
    • 2.5.2 Bharat Serums and Vaccines Major Business
    • 2.5.3 Bharat Serums and Vaccines Equine Immunoglobulin and F(ab')2 Products Product and Services
    • 2.5.4 Bharat Serums and Vaccines Equine Immunoglobulin and F(ab')2 Products Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Bharat Serums and Vaccines Recent Developments/Updates
  • 2.6 KM Biologics
    • 2.6.1 KM Biologics Details
    • 2.6.2 KM Biologics Major Business
    • 2.6.3 KM Biologics Equine Immunoglobulin and F(ab')2 Products Product and Services
    • 2.6.4 KM Biologics Equine Immunoglobulin and F(ab')2 Products Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 KM Biologics Recent Developments/Updates
  • 2.7 Inosan Biopharma
    • 2.7.1 Inosan Biopharma Details
    • 2.7.2 Inosan Biopharma Major Business
    • 2.7.3 Inosan Biopharma Equine Immunoglobulin and F(ab')2 Products Product and Services
    • 2.7.4 Inosan Biopharma Equine Immunoglobulin and F(ab')2 Products Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Inosan Biopharma Recent Developments/Updates
  • 2.8 MicroPharm
    • 2.8.1 MicroPharm Details
    • 2.8.2 MicroPharm Major Business
    • 2.8.3 MicroPharm Equine Immunoglobulin and F(ab')2 Products Product and Services
    • 2.8.4 MicroPharm Equine Immunoglobulin and F(ab')2 Products Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 MicroPharm Recent Developments/Updates

3 Competitive Environment: Equine Immunoglobulin and F(ab')2 Products by Manufacturer

  • 3.1 Global Equine Immunoglobulin and F(ab')2 Products Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Equine Immunoglobulin and F(ab')2 Products Revenue by Manufacturer (2021-2026)
  • 3.3 Global Equine Immunoglobulin and F(ab')2 Products Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Equine Immunoglobulin and F(ab')2 Products by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Equine Immunoglobulin and F(ab')2 Products Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Equine Immunoglobulin and F(ab')2 Products Manufacturer Market Share in 2025
  • 3.5 Equine Immunoglobulin and F(ab')2 Products Market: Overall Company Footprint Analysis
    • 3.5.1 Equine Immunoglobulin and F(ab')2 Products Market: Region Footprint
    • 3.5.2 Equine Immunoglobulin and F(ab')2 Products Market: Company Product Type Footprint
    • 3.5.3 Equine Immunoglobulin and F(ab')2 Products Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Equine Immunoglobulin and F(ab')2 Products Market Size by Region
    • 4.1.1 Global Equine Immunoglobulin and F(ab')2 Products Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Equine Immunoglobulin and F(ab')2 Products Consumption Value by Region (2021-2032)
    • 4.1.3 Global Equine Immunoglobulin and F(ab')2 Products Average Price by Region (2021-2032)
  • 4.2 North America Equine Immunoglobulin and F(ab')2 Products Consumption Value (2021-2032)
  • 4.3 Europe Equine Immunoglobulin and F(ab')2 Products Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Equine Immunoglobulin and F(ab')2 Products Consumption Value (2021-2032)
  • 4.5 South America Equine Immunoglobulin and F(ab')2 Products Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Equine Immunoglobulin and F(ab')2 Products Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Equine Immunoglobulin and F(ab')2 Products Sales Quantity by Type (2021-2032)
  • 5.2 Global Equine Immunoglobulin and F(ab')2 Products Consumption Value by Type (2021-2032)
  • 5.3 Global Equine Immunoglobulin and F(ab')2 Products Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Equine Immunoglobulin and F(ab')2 Products Sales Quantity by Application (2021-2032)
  • 6.2 Global Equine Immunoglobulin and F(ab')2 Products Consumption Value by Application (2021-2032)
  • 6.3 Global Equine Immunoglobulin and F(ab')2 Products Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Equine Immunoglobulin and F(ab')2 Products Sales Quantity by Type (2021-2032)
  • 7.2 North America Equine Immunoglobulin and F(ab')2 Products Sales Quantity by Application (2021-2032)
  • 7.3 North America Equine Immunoglobulin and F(ab')2 Products Market Size by Country
    • 7.3.1 North America Equine Immunoglobulin and F(ab')2 Products Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Equine Immunoglobulin and F(ab')2 Products Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Equine Immunoglobulin and F(ab')2 Products Sales Quantity by Type (2021-2032)
  • 8.2 Europe Equine Immunoglobulin and F(ab')2 Products Sales Quantity by Application (2021-2032)
  • 8.3 Europe Equine Immunoglobulin and F(ab')2 Products Market Size by Country
    • 8.3.1 Europe Equine Immunoglobulin and F(ab')2 Products Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Equine Immunoglobulin and F(ab')2 Products Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Equine Immunoglobulin and F(ab')2 Products Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Equine Immunoglobulin and F(ab')2 Products Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Equine Immunoglobulin and F(ab')2 Products Market Size by Region
    • 9.3.1 Asia-Pacific Equine Immunoglobulin and F(ab')2 Products Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Equine Immunoglobulin and F(ab')2 Products Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Equine Immunoglobulin and F(ab')2 Products Sales Quantity by Type (2021-2032)
  • 10.2 South America Equine Immunoglobulin and F(ab')2 Products Sales Quantity by Application (2021-2032)
  • 10.3 South America Equine Immunoglobulin and F(ab')2 Products Market Size by Country
    • 10.3.1 South America Equine Immunoglobulin and F(ab')2 Products Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Equine Immunoglobulin and F(ab')2 Products Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Equine Immunoglobulin and F(ab')2 Products Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Equine Immunoglobulin and F(ab')2 Products Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Equine Immunoglobulin and F(ab')2 Products Market Size by Country
    • 11.3.1 Middle East & Africa Equine Immunoglobulin and F(ab')2 Products Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Equine Immunoglobulin and F(ab')2 Products Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Equine Immunoglobulin and F(ab')2 Products Market Drivers
  • 12.2 Equine Immunoglobulin and F(ab')2 Products Market Restraints
  • 12.3 Equine Immunoglobulin and F(ab')2 Products Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Equine Immunoglobulin and F(ab')2 Products and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Equine Immunoglobulin and F(ab')2 Products
  • 13.3 Equine Immunoglobulin and F(ab')2 Products Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Equine Immunoglobulin and F(ab')2 Products Typical Distributors
  • 14.3 Equine Immunoglobulin and F(ab')2 Products Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Equine Immunoglobulin and F(ab')2 Products market size was valued at US$ 1484 million in 2025 and is forecast to a readjusted size of US$ 1971 million by 2032 with a CAGR of 4.1% during review period.
    Equine Immunoglobulin and F(ab')2 Fragment Products refer to a class of passive immunotherapy biologics derived from hyperimmune horse plasma obtained after immunization with venoms, bacterial toxins, viral antigens, or related immunogens, followed by purification, enzymatic digestion, viral inactivation, formulation, and sterile filling. Major commercial products include snake antivenoms, equine tetanus immunoglobulin, equine rabies immunoglobulin, and selected antitoxin preparations. Upstream raw materials and inputs mainly include immunized horses, venoms or toxoids/antigens, plasma collection and fractionation materials, enzymes, purification reagents, stabilizers, packaging materials, and cold-chain logistics, while downstream customers are primarily hospital emergency departments, trauma treatment centers, envenomation treatment institutions, public health agencies, and government stockpile systems. The global production capacity for equine immunoglobulin and F(ab')2 products is estimated at approximately 19.4 million vials in 2025, with sales volume of about 15.68 million vials, an average ex-factory price of around US$92 per vial, and gross margins generally in the range of 45%–72%. Overall, this market is characterized by strong regionalization and indication-specific segmentation: developing markets are dominated by high-volume, lower-priced demand, whereas developed markets are more strongly driven by specialized clinical use and public health stockpiling, resulting in higher value-added product demand.
    This report is a detailed and comprehensive analysis for global Equine Immunoglobulin and F(ab')2 Products market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Equine Immunoglobulin and F(ab')2 Products market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Equine Immunoglobulin and F(ab')2 Products market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Equine Immunoglobulin and F(ab')2 Products market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Equine Immunoglobulin and F(ab')2 Products market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Equine Immunoglobulin and F(ab')2 Products
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Equine Immunoglobulin and F(ab')2 Products market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Laboratorios Silanes, Emergent BioSolutions, Shanghai Serum Bio-Technology, VINS Bioproducts, Bharat Serums and Vaccines, KM Biologics, Inosan Biopharma, MicroPharm, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Equine Immunoglobulin and F(ab')2 Products market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Tetanus Antitoxins
    Snake Antivenoms
    Anti-rabies Sera
    Other
    Market segment by Sales Channels
    Online Sales
    Offline Sales
    Market segment by Application
    Hospital
    Clinic
    Others
    Major players covered
    Laboratorios Silanes
    Emergent BioSolutions
    Shanghai Serum Bio-Technology
    VINS Bioproducts
    Bharat Serums and Vaccines
    KM Biologics
    Inosan Biopharma
    MicroPharm
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Equine Immunoglobulin and F(ab')2 Products product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Equine Immunoglobulin and F(ab')2 Products, with price, sales quantity, revenue, and global market share of Equine Immunoglobulin and F(ab')2 Products from 2021 to 2026.
    Chapter 3, the Equine Immunoglobulin and F(ab')2 Products competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Equine Immunoglobulin and F(ab')2 Products breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Equine Immunoglobulin and F(ab')2 Products market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Equine Immunoglobulin and F(ab')2 Products.
    Chapter 14 and 15, to describe Equine Immunoglobulin and F(ab')2 Products sales channel, distributors, customers, research findings and conclusion.

    Buy now